Pulmonary Hypertension in Dogs
Understand pulmonary hypertension in dogs — the physiological mechanisms, evolutionary context, clinical signs, and what the latest veterinary science reveals.
What Is Pulmonary Hypertension in Dogs?
Direct answer: Pulmonary hypertension (PH) in dogs is defined as an abnormal elevation of blood pressure within the pulmonary arteries — the vessels that carry deoxygenated blood from the right side of the heart to the lungs. Normal mean pulmonary artery pressure (mPAP) in healthy dogs ranges from approximately 8–20 mmHg at rest. When mPAP exceeds 25 mmHg, the condition is classified as pulmonary hypertension. This is not a disease in itself but rather a hemodynamic consequence of underlying cardiac, respiratory, parasitic, or systemic disorders. Without treatment, PH progressively overloads the right ventricle, eventually leading to right-sided heart failure (cor pulmonale) and potentially fatal outcomes.
The Physiology of Pulmonary Blood Flow
To understand why pulmonary hypertension develops, you need to follow the path of blood through a dog's cardiopulmonary system. Deoxygenated blood returns from the body via the cranial and caudal vena cava into the right atrium, passes through the tricuspid valve into the right ventricle, and is then pumped through the pulmonary valve into the main pulmonary artery. From there, blood enters the pulmonary arterioles and finally the pulmonary capillaries, where gas exchange occurs across the thin alveolar walls.
The pulmonary circulation is a low-pressure, low-resistance system by design. Unlike the systemic circulation, which must push blood against gravity and through dense capillary beds throughout the body, the pulmonary circuit only needs to perfuse the adjacent lung tissue. The walls of pulmonary arterioles are thin and highly compliant, and under normal conditions, they dilate in response to increased flow rather than constricting.
Pulmonary hypertension arises when this low-resistance architecture is disrupted. The mechanisms fall into several categories, often classified using the Merck Veterinary Manual's framework adapted from the human Dana Point/ACCP classification:
- Precapillary PH: Increased resistance in pulmonary arterioles due to vasoconstriction, vascular remodeling, obstruction (thromboemboli, heartworms), or external compression.
- Postcapillary PH: Elevated left-sided heart pressures (from mitral valve disease, dilated cardiomyopathy, or left-sided congestive heart failure) that back up into the pulmonary veins and capillaries.
- Mixed or multifactorial PH: Commonly seen in dogs with concurrent respiratory disease and cardiac disease.
At the cellular level, chronic hypoxia triggers a cascade involving endothelin-1 (a potent vasoconstrictor), reduced nitric oxide bioavailability, and proliferation of smooth muscle cells in the arteriole walls. This remodeling thickens the vessel walls, narrows the lumen, and creates a self-reinforcing cycle of rising pressure and worsening oxygenation.
Evolutionary Context: Why Canine Lungs Are Vulnerable
Domestic dogs descended from gray wolves (Canis lupus), persistence predators that evolved to cover vast distances across varied terrain and altitudes. The wolf's cardiopulmonary system was shaped by selective pressures favoring efficient oxygen extraction during sustained aerobic exertion — trotting for hours, sometimes across high-altitude landscapes where atmospheric oxygen partial pressure drops significantly.
This evolutionary history produced a pulmonary vascular bed optimized for flow recruitment: when cardiac output increases during exercise, additional pulmonary capillaries open up to accommodate the extra blood flow without a proportional rise in pressure. This is an elegant adaptation — but it comes with a trade-off. The thin-walled, highly distensible pulmonary arterioles that make this possible are structurally vulnerable to remodeling when subjected to chronic hypoxia, inflammation, or mechanical obstruction.
In ancestral environments, pulmonary hypertension would have been vanishingly rare. Wolves with significant cardiopulmonary compromise would not survive to reproduce. Modern dogs, however, live longer (often 12–16 years), encounter novel pathogens (heartworm, respiratory infections), consume diets that contribute to obesity and cardiac disease, and are selectively bred for traits that sometimes compromise thoracic conformation — all of which create conditions under which PH can develop. The condition is, in a sense, a byproduct of the extended lifespans and environmental shifts that define domestication.
How Do Dogs Develop Pulmonary Hypertension?
Dogs do not develop pulmonary hypertension spontaneously. It is always secondary to an underlying process. The most common etiologies seen in veterinary cardiology practice include:
| Cause Category | Specific Conditions | Estimated Frequency in PH Cases |
|---|---|---|
| Left-sided heart disease | Mitral valve disease (MMVD), dilated cardiomyopathy (DCM) | ~40–55% |
| Respiratory disease | Chronic bronchitis, pulmonary fibrosis, laryngeal paralysis, brachycephalic obstructive airway syndrome (BOAS) | ~20–30% |
| Parasitic disease | Heartworm disease (Dirofilaria immitis), pulmonary thromboembolism from adulticide treatment | ~10–15% |
| Thromboembolic | Pulmonary thromboembolism (PTE) secondary to hyperadrenocorticism, IMHA, protein-losing nephropathy, neoplasia | ~8–12% |
| Idiopathic/primary | No identifiable underlying cause (rare in dogs compared to humans) | <5% |
Left-sided heart disease is the single most common cause. In myxomatous mitral valve disease — extremely prevalent in small breeds like Cavalier King Charles Spaniels, Dachshunds, and Miniature Poodles — progressive regurgitation through the mitral valve elevates left atrial pressure. That pressure transmits retrograde through the pulmonary veins and capillaries, eventually raising pulmonary artery pressures. Studies published in the Journal of Veterinary Internal Medicine have shown that approximately 14–30% of dogs with advanced MMVD develop clinically significant PH.
Brachycephalic breeds (English Bulldogs, French Bulldogs, Pugs) face a distinct pathway. Chronic upper airway obstruction from BOAS creates persistently negative intrathoracic pressures during inspiration, which increases venous return to the right heart and promotes pulmonary vascular remodeling over time. Chronic intermittent hypoxia from obstructed breathing further drives vasoconstriction.
What Does It Mean When My Dog Shows These Signs?
The clinical signs of pulmonary hypertension are often subtle early on and overlap with many other cardiopulmonary conditions. This is one reason the condition is underdiagnosed. Key signs include:
- Exercise intolerance: Your dog tires more quickly on walks, sits down mid-walk, or refuses to climb stairs. This reflects the inability of the right ventricle to increase cardiac output against elevated pulmonary resistance.
- Syncope (fainting): Brief episodes of collapse, often triggered by exertion or excitement. This occurs when the right heart cannot deliver sufficient blood to the lungs for oxygenation, causing a transient drop in cerebral perfusion.
- Cough: Often dry and hacking, sometimes worse at night or after activity. Cough can reflect the underlying respiratory disease or cardiac enlargement compressing the mainstem bronchi.
- Tachypnea or dyspnea: Elevated resting respiratory rate (normal sleeping respiratory rate is <30 breaths/minute) or visible effort in breathing.
- Abdominal distension (ascites): Fluid accumulation in the abdomen from right-sided heart failure — a late-stage sign indicating elevated systemic venous pressures.
- Cyanosis: Bluish-purple mucous membranes indicating severely impaired oxygenation — this is an emergency.
- Acute collapse or fainting that lasts more than a few seconds
- Blue or gray gums/tongue (cyanosis)
- Severe difficulty breathing, open-mouth breathing in a non-brachycephalic dog
- Sudden, marked abdominal swelling
- Resting respiratory rate consistently above 40 breaths/minute
How Is Pulmonary Hypertension Diagnosed and Classified?
Definitive diagnosis requires echocardiography (cardiac ultrasound). The gold standard in human medicine — right heart catheterization with direct pressure measurement — is rarely performed in veterinary practice due to cost, invasiveness, and the need for specialized equipment. Instead, veterinary cardiologists rely on Doppler echocardiographic estimates.
Key echocardiographic parameters include:
| Parameter | Normal Range | PH Threshold | What It Measures |
|---|---|---|---|
| Tricuspid regurgitation pressure gradient (TRPG) | <25 mmHg | >36 mmHg suggests systolic PH | Estimates peak systolic pulmonary artery pressure via Bernoulli equation |
| Pulmonary regurgitation velocity | <2.2 m/s (end-diastolic) | >2.2 m/s | Estimates mean pulmonary artery pressure |
| RV:LV ratio (right-to-left ventricular diameter) | <0.6 | >0.8 | Right ventricular dilation indicating chronic pressure overload |
| TAPSE (tricuspid annular plane systolic excursion) | Varies by body weight | Decreased values | Right ventricular systolic function |
| Septal flattening (D-shaped left ventricle) | Absent | Present in systole or diastole | RV pressure or volume overload affecting LV geometry |
Your veterinarian will also run baseline bloodwork (CBC, chemistry, urinalysis), thoracic radiographs to evaluate lung fields and cardiac silhouette, and heartworm antigen testing. Depending on the suspected underlying cause, additional diagnostics may include NT-proBNP (a biomarker of cardiac stretch), D-dimer levels (for thromboembolic disease), or advanced imaging such as CT angiography.
The estimated cost for a complete PH diagnostic workup ranges from $600–$1,500 for baseline tests and echocardiography at a general practice, to $1,200–$3,000+ at a veterinary cardiology specialty center. Advanced imaging (CT angiography) adds $1,500–$2,500.
How Is This Different From Humans?
While the fundamental hemodynamics are similar, several key differences distinguish canine PH from the human condition:
| Aspect | Human Medicine | Veterinary Medicine |
|---|---|---|
| Primary (idiopathic) PH | Recognized as a distinct disease entity (Group 1 PAH) | Extremely rare in dogs; nearly all cases are secondary |
| Most common cause | Group 2 (left heart disease) and Group 3 (lung disease) are most prevalent globally | Left-sided heart disease (especially MMVD) dominates |
| Heartworm as etiology | Not applicable | Significant cause in endemic regions without preventive compliance |
| Diagnostic gold standard | Right heart catheterization (RHC) | Echocardiography (RHC rarely available/performed) |
| Targeted PH therapies | Multiple FDA-approved drug classes (ERAs, PDE5 inhibitors, prostacyclin analogs, sGC stimulators) | Sildenafil is the primary targeted therapy; limited veterinary-specific drug approvals |
| Prognosis tracking | WHO Functional Classification (I–IV) | No universally adopted staging system; clinicians use modified NYHA/ACVIM cardiac staging |
One important physiological difference: dogs have a higher baseline heart rate than humans (70–160 bpm depending on size versus 60–100 bpm in adult humans). This means the right ventricle is already working at a higher frequency, and when pulmonary vascular resistance increases, the myocardial oxygen demand escalates more rapidly. Small-breed dogs, with their inherently faster heart rates, may decompensate more quickly once PH becomes severe.
Treatment Options and Practical Daily Management
Treatment of pulmonary hypertension in dogs rests on two pillars: addressing the underlying cause and providing targeted pulmonary vasodilation.
Addressing the Underlying Cause
This is where the greatest clinical impact occurs. Examples include:
- Heartworm disease: Adulticide therapy (melarsomine protocol) combined with strict exercise restriction. PH often improves after worm burden is eliminated, though severe vascular remodeling may be irreversible.
- Mitral valve disease: Standard CHF therapy (furosemide, pimobendan, ACE inhibitors) reduces left atrial pressure, which in turn decreases postcapillary pulmonary pressures.
- Respiratory disease: Bronchodilators, anti-inflammatory therapy, supplemental oxygen, and in brachycephalic breeds, surgical correction of stenotic nares and elongated soft palate.
- Pulmonary thromboembolism: Anticoagulation (clopidogrel, rivaroxaban, or low-molecular-weight heparin) plus treatment of the underlying prothrombotic condition.
Targeted Pulmonary Vasodilation
Sildenafil (Revatio®/generic) is the cornerstone of targeted PH therapy in dogs. It is a phosphodiesterase-5 (PDE5) inhibitor that increases cyclic GMP in pulmonary vascular smooth muscle, promoting selective vasodilation of the pulmonary bed.
| Dog Weight | Typical Starting Dose | Dose Range | Frequency |
|---|---|---|---|
| 5–10 kg (11–22 lb) | 10 mg | 1–3 mg/kg | Every 8–12 hours |
| 10–20 kg (22–44 lb) | 20 mg | 1–3 mg/kg | Every 8–12 hours |
| 20–35 kg (44–77 lb) | 30–40 mg | 1–3 mg/kg | Every 8–12 hours |
| 35+ kg (77+ lb) | 50 mg | 1–3 mg/kg | Every 8–12 hours |
Note: Your veterinarian will determine the precise dose based on your dog's individual condition, concurrent medications, and echocardiographic response. Never adjust medication doses without veterinary guidance.
Sildenafil costs approximately $15–$60/month depending on dose and pharmacy. Compounded formulations (chew treats, oral suspension) are available for small dogs that cannot take standard tablets.
Additional medications that may be used include:
- Pimobendan: A calcium sensitizer and PDE3 inhibitor with positive inotropic and mild vasodilatory effects. Primarily used for cardiac disease but may benefit PH patients with concurrent systolic dysfunction. Typical dose: 0.25–0.3 mg/kg every 12 hours. Cost: $30–$80/month.
- Tadalafil: A longer-acting PDE5 inhibitor (once-daily dosing). Less studied in dogs than sildenafil but occasionally used when twice-to-thrice-daily dosing is impractical. Cost: $40–$120/month.
- Supplemental oxygen: For acute decompensation or severe hypoxemia. Home oxygen therapy setups (concentrator + cage or mask) cost $300–$800 to purchase, with ongoing electricity costs. Oxygen flow rates typically 50–100 mL/kg/minute via flow-by or mask.
Practical Daily Life Adjustments
- Exercise restriction: Limit to short, gentle leash walks (5–15 minutes). Avoid off-leash play, running, stair climbing, and excitement triggers. The goal is to keep cardiac output within a range the compromised pulmonary vasculature can accommodate.
- Monitor resting respiratory rate: Count breaths per minute while your dog sleeps. Normal is under 30 breaths/minute. A sustained increase above 30–35 suggests worsening congestion or oxygenation and warrants a veterinary call.
- Temperature control: Heat increases metabolic demand and respiratory rate. Keep ambient temperature below 75°F (24°C). Avoid outdoor exercise in warm weather.
- Altitude awareness: Higher elevations reduce atmospheric oxygen partial pressure. Dogs with PH may decompensate at altitudes above 5,000 feet. Discuss travel plans with your veterinarian.
- Stress minimization: Excitement and anxiety raise heart rate and pulmonary pressures. Use calm interactions, avoid situations that trigger barking frenzies, and consider Adaptil pheromone diffusers or veterinarian-recommended anxiolytics if needed.
- Harness instead of collar: Pressure on the trachea from a collar can worsen airway resistance. Use a front-clip harness for any leash activity.
Common Misconceptions Debunked
| Myth | Fact |
|---|---|
| "Pulmonary hypertension is the same as systemic high blood pressure." | They are distinct conditions. Systemic hypertension affects the arteries supplying the body; PH affects only the pulmonary circuit. A dog can have normal systemic blood pressure and severe PH, or vice versa. |
| "If my dog is on heartworm preventive, PH can't be caused by parasites." | While heartworm preventives are highly effective (99%+ when administered correctly), missed doses, vomiting after administration, or drug resistance can result in infection. Additionally, other parasitic conditions (e.g., Angiostrongylus vasorum in endemic regions) can cause PH. |
| "PH is always rapidly fatal." | Prognosis varies enormously depending on the underlying cause and severity. Dogs with mild PH secondary to well-managed MMVD may live 1–3+ years with quality of life. Severe PH with syncope and right heart failure carries a more guarded prognosis, often measured in months. |
| "Supplements like fish oil or CoQ10 can cure PH." | No supplement has demonstrated the ability to reverse pulmonary vascular remodeling in dogs. Omega-3 fatty acids may provide mild anti-inflammatory benefit as adjunctive support, but they are not a treatment for PH. Always discuss supplements with your veterinarian. |
| "Only old dogs get pulmonary hypertension." | While PH is more common in older dogs (reflecting the prevalence of MMVD and chronic respiratory disease), young dogs can develop PH from heartworm disease, congenital heart defects (patent ductus arteriosus with reversed shunt, i.e., Eisenmenger physiology), pulmonary thromboembolism, or severe pneumonia. |
Breed Variations and Predispositions
No breed is immune to pulmonary hypertension, but certain breeds face elevated risk due to their predisposition to underlying conditions:
- Cavalier King Charles Spaniels: Up to 90% develop MMVD by age 10, making this breed disproportionately represented in PH secondary to left heart disease. Screening echocardiograms are recommended annually from age 4–5.
- Brachycephalic breeds (English Bulldogs, French Bulldogs, Pugs, Boston Terriers): Chronic BOAS creates a persistent hypoxic stimulus and abnormal intrathoracic pressure dynamics. French Bulldogs, now the most popular AKC-registered breed, are overrepresented in PH studies related to respiratory causes.
- Doberman Pinschers and Great Danes: Dilated cardiomyopathy predisposes these breeds to left-sided heart failure and secondary PH.
- Heartworm-endemic region breeds: Any breed in the southeastern United States, Gulf Coast, or Mississippi River Valley without consistent heartworm prevention is at risk for heartworm-associated PH. This is an environmental risk, not a genetic one.
- Miniature Schnauzers: Predisposed to hypertriglyceridemia, which increases risk of pancreatitis and subsequent pulmonary thromboembolism.
Prognosis and Long-Term Outlook
Prognosis depends on three primary factors: the underlying cause, the severity of PH at diagnosis, and the response to therapy.
- Mild PH (TRPG 36–50 mmHg) with a treatable underlying cause: Many dogs stabilize for 1–3+ years with appropriate management.
- Moderate PH (TRPG 50–75 mmHg): Median survival varies widely, from 6–18 months depending on comorbidities and treatment response.
- Severe PH (TRPG >75 mmHg) with syncope or right heart failure: Median survival is often 3–12 months, though individual responses to sildenafil and underlying disease management can extend this.
Recheck echocardiograms are typically recommended every 3–6 months to assess treatment response and disease progression. Monitoring resting respiratory rate at home (daily counts while your dog sleeps) provides an inexpensive, noninvasive way to detect early decompensation between veterinary visits.
Frequently Asked Questions
Can dogs survive pulmonary hypertension?
Yes. Many dogs with mild to moderate pulmonary hypertension can live months to years with appropriate treatment of the underlying cause and targeted pulmonary vasodilator therapy. Survival depends heavily on the specific etiology, severity at diagnosis, and individual response to medications. Some dogs with PH secondary to well-managed mitral valve disease maintain good quality of life for over two years after PH diagnosis.
Is pulmonary hypertension in dogs normal?
No. Pulmonary hypertension is always abnormal and always secondary to another condition. Unlike systemic blood pressure, which can rise mildly with stress or pain (a phenomenon called "white coat hypertension"), elevated pulmonary pressures indicate a genuine pathological process that requires investigation and treatment.
How is pulmonary hypertension different from regular heart disease in dogs?
Pulmonary hypertension specifically affects the blood vessels between the heart and lungs. While it often coexists with heart disease (particularly left-sided valve disease), it can also occur independently due to lung disease, heartworms, or blood clots. The distinction matters because PH requires specific treatment (pulmonary vasodilators like sildenafil) beyond standard cardiac medications.
Can I hear or feel my dog's pulmonary hypertension at home?
Not directly. You cannot feel elevated pulmonary pressures. However, a loud or split second heart sound (P2) on the left side of the chest can sometimes indicate elevated pulmonary pressures — this requires a stethoscope and trained ear. What you can observe at home are clinical consequences: exercise intolerance, fainting episodes, coughing, increased breathing rate, and abdominal swelling.
Why do dogs with heartworm disease develop pulmonary hypertension?
Adult heartworms physically reside in the pulmonary arteries and right heart, causing direct mechanical obstruction to blood flow. Additionally, the worms trigger intense inflammatory responses in the vessel walls (pulmonary arteritis), leading to vasoconstriction, thrombus formation, and vascular remodeling. Even after successful adulticide treatment, residual vascular damage can perpetuate PH for months or permanently.
What does it mean when my dog faints during excitement?
Syncope (fainting) in a dog with known or suspected PH typically indicates that the right ventricle cannot increase output sufficiently to meet the body's oxygen demands during surges in activity or excitement. Blood pressure drops transiently, cerebral perfusion falls, and the dog collapses — usually regaining consciousness within seconds. While brief syncope is not immediately life-threatening in isolation, it signals significant hemodynamic compromise and should be reported to your veterinarian promptly for medication adjustment.
Key References
- Merck Veterinary Manual — Pulmonary Hypertension in Dogs
- American Veterinary Medical Association (AVMA) — Dog Care Resources
- Serres, F. et al. "Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001–2005)." Journal of the American Veterinary Medical Association, 229(11), 1765–1771.
This article is for educational purposes only and does not replace professional veterinary advice. If your dog shows signs of exercise intolerance, fainting, difficulty breathing, or coughing, consult your veterinarian for a thorough evaluation. Early diagnosis and treatment of pulmonary hypertension can significantly improve your dog's quality of life and prognosis.
Dr. Hannah Wickes
All our authors care for dogs every day — read more of their work on the authors page.
